Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Expected to Post Quarterly Sales of $680,000.00

Brokerages predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will announce $680,000.00 in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Infinity Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.50 million and the lowest estimate coming in at $200,000.00. Infinity Pharmaceuticals posted sales of $22.00 million in the same quarter last year, which would suggest a negative year over year growth rate of 96.9%. The company is expected to announce its next earnings results on Monday, November 4th.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year sales of $3.73 million for the current financial year, with estimates ranging from $2.00 million to $7.00 million. For the next financial year, analysts expect that the business will post sales of $1.52 million, with estimates ranging from $800,000.00 to $2.23 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Tuesday, July 30th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Infinity Pharmaceuticals had a negative net margin of 77.80% and a negative return on equity of 42.16%. The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $2.60 million.

A number of research firms recently issued reports on INFI. CIBC began coverage on shares of Infinity Pharmaceuticals in a report on Thursday, June 27th. They issued an “outperform” rating for the company. Oppenheimer began coverage on shares of Infinity Pharmaceuticals in a report on Thursday, June 27th. They issued an “outperform” rating and a $3.00 target price for the company. Finally, ValuEngine upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $2.67.

Infinity Pharmaceuticals stock traded up $0.02 during trading on Friday, reaching $1.22. The company had a trading volume of 44,397 shares, compared to its average volume of 63,728. Infinity Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $2.92. The stock’s 50 day moving average price is $1.55 and its two-hundred day moving average price is $1.57. The firm has a market capitalization of $69.01 million, a price-to-earnings ratio of -6.10 and a beta of 1.79. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.93 and a current ratio of 7.93.

Institutional investors have recently added to or reduced their stakes in the stock. Community Bank N.A. grew its holdings in Infinity Pharmaceuticals by 71.4% in the first quarter. Community Bank N.A. now owns 24,000 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 10,000 shares during the period. Parametric Portfolio Associates LLC acquired a new position in Infinity Pharmaceuticals during the second quarter valued at approximately $76,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Infinity Pharmaceuticals by 54.2% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,232 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 15,908 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Infinity Pharmaceuticals by 73.6% during the fourth quarter. Bank of New York Mellon Corp now owns 72,256 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 30,622 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in Infinity Pharmaceuticals by 29.4% during the fourth quarter. Two Sigma Investments LP now owns 91,296 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 20,721 shares in the last quarter. Hedge funds and other institutional investors own 54.17% of the company’s stock.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Recommended Story: What do I need to know about analyst ratings?

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.